Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

1,864JPY
2:00am EDT
Change (% chg)

¥26 (+1.41%)
Prev Close
¥1,838
Open
¥1,847
Day's High
¥1,867
Day's Low
¥1,842
Volume
1,325,100
Avg. Vol
1,186,841
52-wk High
¥2,131
52-wk Low
¥1,424

Select another date:

Fri, Aug 25 2017

BRIEF- R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

BRIEF-Ultragenyx, Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in U.S.

* Ultragenyx and Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in the U.S.

BRIEF-Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei

* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen

BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab

* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia

BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its primary endpoint

* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint

Select another date: